Canada markets closed

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
8.35-0.09 (-1.07%)
At close: 03:39PM EST
Full screen
Previous Close8.44
Bid8.35 x 0
Ask8.50 x 0
Day's Range8.35 - 8.50
52 Week Range6.76 - 9.59
Avg. Volume4,890
Market Cap105.167M
Beta (5Y Monthly)0.97
PE Ratio (TTM)21.19
EPS (TTM)0.39
Earnings DateNov. 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Simply Wall St.

    Do Its Financials Have Any Role To Play In Driving BioSyent Inc.'s (CVE:RX) Stock Up Recently?

    BioSyent's (CVE:RX) stock is up by a considerable 21% over the past month. We wonder if and what role the company's...

  • GlobeNewswire

    BioSyent Releases Q3 and YTD 2021 Financial Results

    MISSISSAUGA, Ontario, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include: Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3 2020Year-to-date (YTD) 2021 Net Revenues of $21,399,562 increased by 29% versus YTD 2020Canadian Pharmaceutical Net Revenues in Q3 2021 of $6,409,809 increased by 17% versus Q3 2020YTD 2021 Canadian Pharma

  • GlobeNewswire

    BioSyent Schedules Q3 and YTD 2021 Earnings Release for November 18, 2021

    MISSISSAUGA, Ontario, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2021 on Thursday, November 18, 2021 at 5:00pm ET. A presentation on the Company’s third quarter and year-to-date 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchan